Atea Pharmaceuticals, Inc. (AVIR) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	351.4	48.6	0.0	0.0
Revenue growth	-100.0%	622.5%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	351.4	48.6	0.0	0.0
Gross margin		100.0%	100.0%
Selling, general and administrative [+]	130.7	213.0	59.7	4.4	2.8
General and administrative				4.4	2.8
Research and development				10.2	6.7
Other operating expenses	11.2	0.2	0.1
EBITDA [+]	-141.5	138.2	-11.1	-14.6	-9.5
EBITDA growth	-202.4%	-1345.7%	-24.0%	54.2%
EBITDA margin		39.3%	-22.8%
Depreciation and amortization	0.3	0.0	0.0	0.0	0.0
EBIT [+]	-141.8	138.2	-11.1	-14.6	-9.5
EBIT growth	-202.6%	-1343.3%	-23.9%	54.1%
EBIT margin		39.3%	-22.9%
Interest income	11.2	0.2	0.1	0.6	0.4
Interest income	11.2	0.2	0.1	0.6	0.4
Other income (expense), net	11.2	0.2	0.1
Pre-tax income	-119.5	138.6	-10.9	-14.0	-9.1
Income taxes	-3.6	17.4	0.0	0.0	0.0
Tax rate	3.0%	12.6%	0.0%	0.0%	0.0%
Net income	-115.9	121.2	-10.9	-14.0	-9.1
Net margin		34.5%	-22.5%

Basic EPS [+]	($1.39)	$1.46	($0.51)	($1.39)	($0.90)
Growth	-195.2%	-388.6%	-63.5%	54.0%
Diluted EPS [+]	($1.39)	$1.37	($0.51)	($1.39)	($0.90)
Growth	-201.4%	-370.9%	-63.5%	54.0%

Shares outstanding (basic) [+]	83.2	82.8	21.6	10.1	10.0
Growth	0.5%	283.6%	114.0%	0.5%
Shares outstanding (diluted) [+]	83.2	88.2	21.6	10.1	10.0
Growth	-5.7%	308.7%	114.0%	0.5%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.